Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma - Contacts and Locations

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

This study is ongoing, but not recruiting participants.
Information provided by Dana-Farber Cancer Institute

Please refer to this study by its ClinicalTrials.gov identifier: NCT00137826

Locations


United States, Illinois
	The University of Chicago
	Chicago, Illinois, United States, 60637

United States, Massachusetts
	Dana-Farber Cancer Institute
	Boston, Massachusetts, United States, 02115
	Massachusetts General Hospital
	Boston, Massachusetts, United States, 02114

Sponsors and Collaborators

Dana-Farber Cancer Institute

Massachusetts General Hospital

University of Chicago

Investigators


Principal Investigator:	Pasi A Janne, MD, PhD	Dana-Farber Cancer Institute